Join Eupraxia Pharmaceuticals for a virtual investor event at Digestive Disease Week (DDW) held May 2-5, 2026, in Chicago, Illinois. The event will feature key opinion leaders (KOLs) Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) and Jeffrey D. Mosko, MD, MSc, FRCPC (University of Toronto), who will discuss the definition, prevalence, and treatment of recurrent esophageal strictures.

Company management will also highlight the potential of its lead product candidate EP-104GI for the prevention of esophageal strictures. EP-104GI is a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues, which has the potential to increase patient adherence by requiring fewer interventions while addressing local inflammation.

A live question and answer session will follow the formal presentations.